clinical trial · NCT05262387
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Eli Lilly and Company·phase1·completed·n = 25
Diabetes Mellitus, Type 1Lyumjev with 50% basal rate reductionHumalog with 50% basal rate reductionHumalog with 100% basal rate reductionLyumjev with 100% basal rate reduction
brief summary
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise using different approaches on basal rate reduction and following a test meal compared to insulin lispro (Humalog). The study may last up to approximately 10 weeks and may include up to 7 visits.
started
Feb 14, 2022
primary completion
Mar 7, 2023
completion
Mar 7, 2023
last updated
Sep 3, 2024
official title
Effectiveness of a Basal Rate Reduction With LyumjevTM Versus Humalog® on the Protection From Exercise-Induced Hypoglycemia in Individuals With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol